Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 8/20 | 0.73 |
| ▸ | CCNC | P24863 | 1/20 | 0.73 |
| ▸ | CDK8 | P49336 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | CD38 | P28907 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13283258 | 0.91 | LMNA (0.83) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL13283187 | 0.86 | LMNA (0.75) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL13874409 | 0.84 | HTT (0.73) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL4359487 | 0.84 | HTT (1.00) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL1585442 | 0.83 | LMNA (0.71) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL19723126 | 0.83 | LMNA (0.71) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL13621683 | 0.82 | RXFP1 (0.79) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL4359385 | 0.82 | HTT (0.83) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL13283185 | 0.81 | HTT (0.68) | LMNAMAPTHTTCCNCCDK8 | |
| SCHEMBL13621680 | 0.81 | HTT (0.72) | LMNAMAPTHTTCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | SENEX BIOTECHNOLOGY, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | SENEX BIOTECHNOLOGY, INC. | 2009-11-12 | — | — | US | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080033000-A1 | Identification of CDKI pathway inhibitors | SENEX BIOTECHNOLOGY, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | LMNA 2411/4885MAPT 3105/4885HTT 4182/4885 |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | LMNA 1964/4885MAPT 3445/4885HTT 1817/4885 |
| US-20100190807-A1 | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein | MAPT, CDK5, CDKN1A | LMNA 2105/4885MAPT 1/4885HTT 292/4885 |
| US-20090281129-A1 | CDKI PATHWAY INHIBITORS AND USES THEREOF | CDKN1A, CDK6, CCNI | LMNA 1622/4885MAPT 1424/4885HTT 930/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | LMNA 1139/4885MAPT 3763/4885HTT 4067/4885 |
| US-20080033000-A1 | Identification of CDKI pathway inhibitors | CDKN1A, CDK6, CDK2 | LMNA 1521/4885MAPT 1548/4885HTT 1550/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | LMNA 2411/4885MAPT 3105/4885HTT 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.